Hycamtin - Big Patent Expirations of 2010

Drug: Hycamtin
Company: GlaxoSmithKline
Indication: Ovarian and small-cell lung cancer
Expiration Date: May 28/Pediatric Exclusivity through Nov. 28

Summary: The '758 patent covering Hycamtin enjoys pediatric exclusivity until November. However, according to the [email protected] website, no generic company has tentative approval for Hycamtin, which is used to treat ovarian and small-cell lung cancer. The product had sales of $72 million in 2009, according to a GSK earnings statement. Teva has tried to get samples of the drug to see if it can make a copy, but GSK has refused. The FTC said last fall it would look into to see whether GSK's actions unfairly thwart competition.

Hycamtin - Big Patent Expirations of 2010
Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.